ADARx Pharmaceuticals reported a significant increase in cash and cash equivalents to $570.6 million as of September 30, 2026, following its initial public offering and concurrent private placement. The company is advancing a clinical pipeline including onvuzosiran (Phase 3) and agazisiran (Phase 2), supported by a major collaboration with AbbVie that contributed to $326.4 million in total deferred revenue.
ADARx Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $611.8 million following its IPO and concurrent private placement with AbbVie. The company is advancing three Phase 2 clinical trials for agazisiran and received FDA Fast Track designation for onvuzosiran in hereditary angioedema.
“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline.”
Zhen Li, Ph.D., President and Chief Executive Officer of ADARx
“As the siRNA field evolves, we see tremendous opportunity to expand the range of diseases these therapeutics can address. We believe that our progress with differentiated liver-targeted programs and targeted delivery to extrahepatic tissues positions us to advance our mission of delivering life-changing treatments to patients with unmet medical needs.”
Zhen Li, Ph.D., President and Chief Executive Officer of ADARx